SOX2 and central nervous system cancer: While the proportion of Nanog+/Sox2+ cells was similar in a grade II and a grade IV tumor (Fig. 3A–C), the amount of Sox2+ cells expressing Oct4 was increased from below 5% in grade II gliomas to above 50% in grade IV tumors (Fig. 3E–G).